• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

    4.460 -0.270 (-5.71%)
    Streaming Delayed Price Updated: 11:42 AM EDT, Mar 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about SciSparc Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    News headline image
    SciSparc To Acquire AutoMax, A Strategic Leap Towards Industry Diversification ↗
    SciSparc to acquire AutoMax Motors, forming a new entity with SciSparc owning over 50%. SciSparc's core operations to continue. 
    Via Benzinga
    News headline image
    SciSparc to Acquire AutoMax
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket ↗
    Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant... 
    Via Benzinga
    News headline image
    SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Why Is SciSparc (SPRC) Stock Up 50% Today? ↗
    News of an investment fund inking an equity purchase agreement with SciSparc is boosting underlying credibility and lifting SPRC stock. 
    Via InvestorPlace
    News headline image
    SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors ↗
     
    Via Benzinga
    News headline image
    SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Autism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New Treatments ↗
    The first patient has been enrolled in SciSparc Ltd.'s clinical trial evaluating the effectiveness and safety of their CBD-based drug for treating children with autism spectrum disorder, marking a... 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗
     
    Via Benzinga
    News headline image
    SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds ↗
    Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗
    SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health. 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? ↗
    SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration... 
    Via Benzinga
    Topics Intellectual Property
    News headline image
    Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
    Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. 
    Via Benzinga
    News headline image
    Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
    From SciSparc Ltd
    Via GlobeNewswire
    News headline image
    Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗
    Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
    Via Benzinga
    News headline image
    Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
    Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares... 
    Via Benzinga
    News headline image
    Crude Oil Rises Over 1%; DuPont Shares Plunge ↗
    U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday. The Dow traded up 0.36% to 38,040.66 while the NASDAQ rose 0.97% to 15,574.97. The... 
    Via Benzinga
    Topics Stocks
    News headline image
    Why SciSparc Stock Is Lighting Up ↗
    SciSparc Ltd. shares are trading higher Wednesday after the company announced that it has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors... 
    Via Benzinga
    News headline image
    Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales ↗
    U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.29% to 38,013.76 while the NASDAQ... 
    Via Benzinga
    Topics Stocks
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.